{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:53:48Z","timestamp":1791320028163,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clgc.2026.102680","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:03:26Z","timestamp":1789398206000},"page":"102680","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rescue Plerixafor-based Mobilization and Outcomes of Salvage High-dose Chemotherapy in Relapsed\/Refractory Germ Cell Tumors: A Large Single-center Experience"],"prefix":"10.1016","volume":"24","author":[{"given":"Sara","family":"Bleve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Menna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9496-6719","authenticated-orcid":false,"given":"Caterina","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9973-4869","authenticated-orcid":false,"given":"Giuseppe","family":"Schepisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Gall\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-749X","authenticated-orcid":false,"given":"Chiara","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Mangianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Baravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Accursio Fabio","family":"Augello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-7167","authenticated-orcid":false,"given":"Francesco","family":"Lanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2097-2803","authenticated-orcid":false,"given":"Giovanni","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9594-1451","authenticated-orcid":false,"given":"Ismaela Anna","family":"Vascotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-2908","authenticated-orcid":false,"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102680_bib0001","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2014.56.0896","article-title":"Testicular cancer: a reflection on 50 years of discovery","volume":"32","author":"Hanna","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","article-title":"Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oldenburg","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2026.102680_bib0003","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/JCO-25-02159","article-title":"Impact of circulating tumor DNA and copy-number alterations on clinical outcome in relapsed\/refractory germ cell tumors treated with salvage high-dose chemotherapy","volume":"44","author":"Urbini","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0004","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clgc.2026.102680_bib0005","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1200\/JCO.2005.19.638","article-title":"Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors","volume":"23","author":"Kondagunta","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0006","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.eururo.2006.05.011","article-title":"Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor","volume":"50","author":"De Giorgi","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102680_bib0007","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14737140.2021.1838279","article-title":"Promising novel therapies for relapsed and refractory testicular germ cell tumors","volume":"21","author":"Kozakova","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2026.102680_bib0008","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0009","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/bmt.2012.21","article-title":"Efficacy and safety of hematopoietic stem cell remobilization with plerixafor plus G-CSF in adult patients with germ cell tumors","volume":"47","author":"Horwitz","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102680_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/bmb\/ldp040","article-title":"Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies","volume":"93","author":"Leung","year":"2010","journal-title":"Br Med Bull"},{"key":"10.1016\/j.clgc.2026.102680_bib0011","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clgc.2026.102680_bib0012","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0013","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/bmt.2010.264","article-title":"Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients","volume":"46","author":"Kobold","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102680_bib0014","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3892\/mco.2014.362","article-title":"Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors","volume":"2","author":"Garc\u00eda-Escobar","year":"2014","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0015","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1111\/j.1537-2995.2012.03603.x","article-title":"European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization","volume":"52","author":"Worel","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.clgc.2026.102680_bib0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/phar.1332","article-title":"Experience with plerixafor for hematopoietic cell mobilization in nine patients with germ cell tumors","volume":"34","author":"O\u2019Hara","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.clgc.2026.102680_bib0017","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/bmt.2011.82","article-title":"Proposed definition of \u2018poor mobilizer\u2019 in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo","volume":"47","author":"Olivieri","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102680_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clgc.2018.09.009","article-title":"Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era","volume":"17","author":"Hamid","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2026.102680_bib0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.transci.2015.05.011","article-title":"Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor","volume":"53","author":"Goker","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clgc.2026.102680_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102680_bib0021","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdm472","article-title":"Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors: results of the sCR2 international study","volume":"19","author":"Fizazi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0022","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/annonc\/mdi017","article-title":"Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience","volume":"16","author":"De Giorgi","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0023","doi-asserted-by":"crossref","first-page":"4906","DOI":"10.1200\/JCO.2009.26.8128","article-title":"Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy","volume":"28","author":"Lorch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0024","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.1996.14.10.2638","article-title":"High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables","volume":"14","author":"Beyer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102680_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jca.21952","article-title":"Successful ``on-demand'' plerixafor for autologous peripheral blood stem-cells transplantation for relapsed\/refractory germ cell tumors","volume":"37","author":"Corbingi","year":"2022","journal-title":"J Clin Apher"},{"key":"10.1016\/j.clgc.2026.102680_bib0026","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41409-022-01614-9","article-title":"Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients","volume":"57","author":"Madanchi","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2026.102680_bib0027","first-page":"697","article-title":"Anticancer drug delivery with nanoparticles","volume":"20","author":"Conti","year":"2006","journal-title":"In Vivo"},{"issue":"7","key":"10.1016\/j.clgc.2026.102680_bib0028","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1039\/C9BM01418G","article-title":"Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously","volume":"1","author":"Jiang","year":"2019","journal-title":"Biomater Sci"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:33:15Z","timestamp":1791318795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1558767326001801"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102680","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue Plerixafor-based Mobilization and Outcomes of Salvage High-dose Chemotherapy in Relapsed\/Refractory Germ Cell Tumors: A Large Single-center Experience","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102680","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102680"}}